openPR Logo
Press release

Lawsuit filed for Investors in shares of Abiomed, Inc. (NASDAQ: ABMD)

08-15-2019 12:09 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Abiomed, Inc. (NASDAQ: ABMD) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Abiomed, Inc. (NASDAQ: ABMD) shares over alleged securities laws violations.

An investor, who purchased shares of Abiomed, Inc. (NASDAQ: ABMD), filed a lawsuit over alleged violations of Federal Securities Laws by Abiomed, Inc.

Investors who purchased shares of Abiomed, Inc. (NASDAQ: ABMD) have certain options and for certain investors are short and strict deadlines running. Deadline: October 7, 2019. NASDAQ: ABMD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On August 1, 2019, pre Abiomed, Inc. announced its financial and operating results for the first quarter of fiscal year 2020. Among other results, Abiomed, Inc. reported “first-quarter fiscal 2020 revenue of $207.7 million, an increase of 15.4% compared to revenue of $180.0 million for the same period of fiscal 2019”. This represented a significant decrease in revenue growth from 2Q 2019. Commenting on the Company’s surprising financial result disappointment, the Company’s Chairman, President, and CEO, Defendant Michael R. Minogue (“Minogue”), revealed that the Company’s “new training programs, organizational changes in distribution, and [] external initiatives… will require time to drive more growth in the future”.
Abiomed, Inc. also slashed its previously issued full-year 2020 guidance from total revenues in the range of $900-945 million to total revenues in the range of $885-925 million, which fell roughly $22 million short of market expectations.
Following the Company’s disclosure of its 1Q 2020 financial performance and revised guidance, Investor’s Business Daily published an article raising concern with Defendant Minogue’s prior public statements, titled: “This Medtech's CEO Promised To ‘Correct The Course’ — That Didn't Happen”.

The plaintiff claims that between January 31, 2019 through July 31, 2019, the defendants made false and/or misleading statements and/or failed to disclose that ABIOMED’s revenue growth was in decline, that the Company did not have a sufficient plan in place to stem its declining revenue growth, that the Company was unlikely to restore its revenue growth over the next several fiscal quarters, that consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Abiomed, Inc. (NASDAQ: ABMD) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Abiomed, Inc. (NASDAQ: ABMD) here

News-ID: 1822415 • Views: 335

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in NYSE: TAP shares over potenti …
An investigation was announced for current long-term investors in shares of Molson Coors Brewing Company (NYSE: TAP) concerning potential breaches of fiduciary duties by certain directors of Molson Coors Brewing Company. Investors who are current long term investors in Molson Coors Brewing Company (NYSE: TAP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current
Investigation announced for long-term Investors in shares of Spectrum Brands Hol …
An investigation on behalf of current long-term investors in shares of Spectrum Brands Holdings, Inc. (NYSE: SPB) concerning potential breaches of fiduciary duties by certain directors and officers of Spectrum Brands Holdings, Inc. was announced. Investors who are current long term investors in Spectrum Brands Holdings, Inc. (NYSE: SPB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a
Deadline on August 26th upcoming in Lawsuit filed for Investors in FedEx Corpora …
The Shareholders Foundation announces that a deadline is coming up on August 26, 2019 in the lawsuit filed for certain investors of FedEx Corporation (NYSE: FDX) over alleged securities laws violations by FedEx. Investors who purchased shares of FedEx Corporation (NYSE: FDX) have certain options and there are strict and short deadlines running. Deadline: August 26, 2019. NYSE: FDX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Lawsuit filed for Investors who purchased shares of 3M Company (NYSE: MMM)
An investor, who purchased shares of 3M Company (NYSE: MMM), filed a lawsuit over alleged violations of Federal Securities Laws by 3M Company in connection with certain allegedly false and misleading statements. Investors who purchased shares of 3M Company (NYSE: MMM) have certain options and for certain investors are short and strict deadlines running. Deadline: September 27, 2019. NYSE: MMM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Abiomed

Bionic Devices Market Analysis and Growth to 2025: by Key Companies Abiomed, Act …
The research study offers powerful guidelines for market players to compete well against other participants operating in the global Bionic Devices market. It brings to light crucial market dynamics including drivers, challenges, restraints, trends, and opportunities. Readers are provided with detailed qualitative and quantitative analysis, PESTLE analysis, absolute dollar opportunity analysis, and Porter’s Five Forces analysis that focus on various aspects of the global Bionic Devices Market. The report includes
Global Total Artificial Heart Market Research Report 2018: BiVACOR, SynCardia, J …
Qyresearchreports include new market research report Global Total Artificial Heart Market Research Report 2018 to its huge collection of research reports. This report studies the global Total Artificial Heart market status and forecast, categorizes the global Total Artificial Heart market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Total Artificial
Global Automotive 48V System Market 2018-2025 Valeo, Bosch, Abiomed
The Global Automotive 48V System Market Report 2018 published by Markets Research Biz is a complete study of the business sectors, 2012-2018. It analyses the important factors of the Automotive 48V System Market based on present industry, Automotive 48V System Market demands, business strategies utilized by Automotive 48V System Market players and the future prospects from various angles in detail. Industry analysis is a market assessment tool used by business and
Heart Pump Devices Market Grows with Medtronic, Abbott, Abiomed, Getinge, Syncar …
The Heart Pump Devices Market is expected to register a CAGR of 12.5% during the forecast period. Heart Pump Devices are mechanical pumps that are used to support the function of the heart and blood flow in individuals with unhealthy hearts. Heart pump devices receive blood from the lower chamber of the heart and pump it to the body and vital organs. Get Sample Report @ https://www.marketresearchfuture.com/sample_request/6034 Heart Pump Devices Market -
World High-pressure Valves Market 2018 - Danfoss, Graco, Abiomed
Apex Market Reports, recently published a detailed market research study focused on the “High-pressure Valves Market” across the World, regional and country level. The report provides 360° analysis of “High-pressure Valves Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the World PP Pipe industry, and estimates the future trend of High-pressure Valves on
Global Thoracic Surgery Market 2018 - Terumo, Abbott Vascular, Abiomed, AtriCure
Global Thoracic Surgery Market 2018 Analysis Report audits a Market Regions, Product Categories, with Sales, Business Revenue, Goods cost, Thoracic Surgery piece of the overall industry and Growth patterns, concentrating on driving Thoracic Surgery industry players, showcase size, request and supply examination, utilization volume, Forecast 2017 to 2025. The major regions present in the continents like United States, Germany, Japan and China and their contribution to global Thoracic Surgery market is